3 results
Primary Objective:To induce clinical response (CDAI decrease from baseline * 100 points) and/or remission(CDAI <150) following 12 weeks of treatment with one of two active doses ofGSK1605786A for qualification of subjects for enrolment into a…
Primary: To evaluate the safety and tolerability of LY3045697 after multiple oral dosing in healthy subjectsSecondary: To investigate the pharmacokinetics of LY3045697 after multiple oral dosing in healthy subjects
The primary objective of this study is to investigate the role of the MR in memory performance under stressful and non-stressful conditions in humans. More specifically the following question will be answered: What effects does the MR antagonist…